Condensed Consolidated Balance Sheets (unaudited) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash	$ 136,870,000	$ 19,868,000
Grants receivable	212,000	5,196,000
R&D tax credits receivable	133,000	133,000
Prepaid expenses and other current assets	3,180,000	879,000
Total current assets	140,395,000	26,076,000
Property and equipment, net	1,251,000	1,336,000
R&D tax credits receivable	3,172,000	2,917,000
Restricted cash	123,000	122,000
Other assets	270,000	293,000
Total assets	145,211,000	30,744,000
Current liabilities:
Accounts payable	2,656,000	1,174,000
Accrued expenses and other current liabilities	3,360,000	4,262,000
Preferred stock tranche rights liability		5,400,000
Deferred income	1,500,000	2,360,000
Total current liabilities	7,516,000	13,196,000
Grants repayable	4,161,000	1,397,000
Other noncurrent liabilities	484,000	482,000
Total liabilities	12,161,000	15,075,000
Commitments and contingencies (Note 9)
Stockholders’ deficit:
Common stock, $0.001 par value, 90,000,000 and 50,000,000 shares authorized at June 30, 2020 and December 31, 2019, respectively; 388,415 and 256,548 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively	1,000	1,000
Additional paid-in capital	687,000
Accumulated other comprehensive loss	(296,000)	(224,000)
Accumulated deficit	(48,314,000)	(35,865,000)
Total stockholders’ deficit	(47,922,000)	(36,088,000)
Total liabilities, redeemable convertible preferred stock and stockholders’ deficit	145,211,000	30,744,000
Series B-2 Preferred Stock
Redeemable convertible preferred stock:
Redeemable convertible preferred stock, value	127,090,000
Series B Preferred Stock
Redeemable convertible preferred stock:
Redeemable convertible preferred stock, value	48,529,000	46,404,000
Series A-1 and A-2 Preferred Stock
Redeemable convertible preferred stock:
Redeemable convertible preferred stock, value	$ 5,353,000	$ 5,353,000